Niagen Bioscience (NAGE) Treasury Shares (2011 - 2026)
Niagen Bioscience (NAGE) reported Treasury Shares of $490000.0 for Q1 2026, up 42.44% year-over-year from $344000.0 in Q1 2025, and up 82.84% quarter-over-quarter from $268000.0 in Q4 2025.
Niagen Bioscience (NAGE) Treasury Shares (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 10 years of Treasury Shares data on file, last reported at $490000.0 in Q1 2026.
- Treasury Shares for Q1 2026 came in at $490000.0, up 42.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $490000.0 (up 42.44% YoY), and the FY2025 annual result was $268000.0, down 55.99% from the prior year.
- Treasury Shares rose to $490000.0 in Q1 2026 per NAGE's latest filing, from $268000.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $1.5 million in Q2 2025 and troughed at $167000.0 in Q3 2023.
- A 5-year average of $678769.2 and a median of $609000.0 in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2025: Treasury Shares jumped 309.58% in 2024, then plunged 61.52% in 2025.
- A 5-year view of Treasury Shares shows it stood at $183000.0 in 2022, then surged by 221.86% to $589000.0 in 2023, then rose by 3.4% to $609000.0 in 2024, then sank by 55.99% to $268000.0 in 2025, then jumped by 82.84% to $490000.0 in 2026.
- Business Quant data shows NAGE's Treasury Shares at $490000.0 in Q1 2026, $268000.0 in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Niagen Bioscience | 269.32 Mn | 202.77 Mn | 19.98 Mn | 490,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 490,000.00 |
| Mar 31, 2026 | 490,000.00 |
| Dec 31, 2025 | 268,000.00 |
| Dec 31, 2025 | 268,000.00 |
| Sep 30, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 344,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Dec 31, 2024 | 609,000.00 |
| Dec 31, 2024 | 609,000.00 |
| Sep 30, 2024 | 684,000.00 |
| Sep 30, 2024 | 684,000.00 |
| Jun 30, 2024 | 784,000.00 |
| Jun 30, 2024 | 784,000.00 |
| Mar 31, 2024 | 894,000.00 |
| Mar 31, 2024 | 894,000.00 |
| Dec 31, 2023 | 589,000.00 |
| Dec 31, 2023 | 589,000.00 |